Advancing the Science of Eye Care

MOA serves as a resource for pharmaceutical and medical device companies seeking research partners for FDA and other clinical trials. Participation in these studies offers MOA patients access to additional leading-edge testing and treatment options and, in some cases, the potential to earn compensation.

If you are interested in being considered for current or future studies, contact MOA’s Clinical Research Study Coordinator, Heather Bollinger at hbollinger@medodamerica.com or call 717-759-5929.

Active Enrollment

There are currently no active studies at this time.

Completed Studies

Demodex TARSUS

This study compares the safety and effectiveness of two different dosing regimens of a treatment for Meibomian Gland Dysfunction in patients with Demodex Blepharitis.

TRINITY Demodex

The study centered around a comprehensive online survey for patients with diagnosed Demodex Blepharitis to learn about different aspects of the patients’ diagnosis, treatment and ongoing care.

Dry Eye Treatment Comparison Study

Effectiveness of TearCare procedures compared to Restasis to treat signs and symptoms of Dry Eye Disease in adult patients.

Dry Eye Flare Questionnaire Study

The Dry Eye Flare Questionnaire is a patient focused questionnaire to learn more about flares, a period of time when dry eye symptoms heighten for a dry eye patient. The study assessed how frequently flares occurred and how patients described their individual symptoms during flares.

TELESCOPE Age-Related Macular Degeneration Trial

A patient identification study primarily designed to identify patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Geographic atrophy is an advanced form of AMD and a leading cause of blindness, without any currently approved therapies.

MIRA–Phase 3 Trial for Mydriasis Medication

Pharmacologically induced mydriasis, a key aspect of ophthalmologic exams and procedures, can lead to photophobia, discomfort and impairment of vision. Depending on the individual and the color of their eyes, the effects of dilation can last anywhere from 6 to over 24 hours. Currently, there are no available options to safely reverse mydriasis. The MIRA-3 study assessed the efficacy of 0.75% phentolamine ophthalmic solution (POS) to reverse pharmacologically induced mydriasis.

Take Part

If you’re interested in taking part in one of our studies, please fill out the contact form and one of our team members will get back to you promptly.

Our Testimonials

Name: Medical Optometry America
Address: 781 Far Hills Drive Suite 100, New Freedom, PA, 17349
Telephone: 717-759-5929

Outstanding services provided from the moment I arrived. Facility is very nice! The modern aesthetic is pleasing to the eye and calming as well! The Staff is Professional, compassionate, and reassuring. I arrived to my appointment concerned about what may be found, regarding my vision. My concerns were thoroughly addressed, investigated and diagnosed. I’m very happy with the treatment plan and have experienced positive results by following Dr. O’Dell’s recommendations. Thank you all so much for a wonderful experience!

Chris

This was my first eye evaluation and it could not have gone any smoother. Testing and results were thoroughly explained and I didn’t have any questions when I left the office. Office was brand new and the staff was very helpful and courteous. If you need an eye exam give them a call!

Paul

Dr. Kuc has been such a great help in assuring me that there are many treatment options for my dry eye! He has helped me feel confident that we will find the right treatment for me and has been thorough in explaining my options and taking the time to answer my questions. He is very good at explaining procedures to put me at ease. He has wonderful “bedside manner” and is one of the most personable and compassionate doctors I think I have ever been to. Very thankful I found Dr. Kuc!

Clinical Trials